PDR001
PDR001 is a pharmaceutical drug with 39 clinical trials. Currently 4 active trials ongoing. Historical success rate of 54.8%.
Success Metrics
Based on 17 completed trials
Phase Distribution
Phase Distribution
30
Early Stage
9
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
53.1%
17 of 32 finished
46.9%
15 ended early
4
trials recruiting
39
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Clinical Trials (39)
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 39